1 option
CADTH Canadian Drug Expert Committee recommendation : indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies Ranolazine (Corzyna -- KYE pharmaceuticals Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Series:
- Common drug review clinical review report.
- Common drug review clinical review report
- Language:
- English
- Subjects (All):
- Angina pectoris.
- Physical Description:
- 1 online resource (7 pages).
- Edition:
- Version: final.
- Other Title:
- CADTH Canadian Drug Expert Committee recommendation
- Place of Publication:
- Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
- Notes:
- Description based on online resource; title from PDF title page (Canadian Agency for Drugs and Technologies in Health, viewed April 22, 2023).
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.